

PA007ITRI05
VL7516

For more information, visit us at www.lillyindia.co.in

Insulin Lispro Injection I.P. (r-DNA origin) Humalog® (100 IU/mL, 3 mL Cartridge) [Monocomponent Insulin lispro, recombinant DNA origin]

NAME OF THE MEDICINAL PRODUCT

Humalog® 100 IU/mL, solution for injection in cartridge

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL of Insulin Lispro contains: 100 IU (equivalent to 3.5 mg) Insulin Lispro I.P. (r-DNA origin) as active ingredient, 16 mg Glycerol I.P. as tonicity modifier, 3.15 mg Metacresol USP as preservative/stabilizer, Zinc Oxide I.P. q.s. as stabilizer, 1.88 mg Dibasic Sodium Phosphate I.P. as buffering agent, Hydrochloric Acid I.P. (10 %) q.s. and Sodium Hydroxide I.P. (10 %) q.s. for pH adjustment, Water for Injection I.P. q.s. 1mL.

Insulin Lispro is synthesized in a special non-disease producing laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for Insulin Lispro production.

PHARMACEUTICAL FORM

Solution for injection. Humalog® is a sterile, clear, colourless, aqueous solution.

CLINICAL PARTICULARS

Therapeutic indications

Humalog® is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog® is also indicated for the initial stabilisation of diabetes mellitus.

Posology and method of administration

The dosage should be determined by the physician, according to the requirement of the patient.

Humalog® may be given shortly before meals. When necessary Humalog® can be given soon after meals. Humalog® preparations should be given by subcutaneous injection or by continuous subcutaneous infusion pump (see section *Instructions for use, handling and Disposal*) and may, although not recommended, also be given by intramuscular injection. If necessary, Humalog® may also be administered intravenously, for example; for the control of blood glucose levels during ketoacidosis, acute illnesses or during intra and post operative periods.

Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month. When administered subcutaneously care should be taken when injecting Humalog® to ensure that a blood vessel has not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use the proper injection techniques.

Humalog® takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously as compared with regular insulin. This rapid onset of activity allows a Humalog® injection (or, in the case of administration by continuous subcutaneous infusion, a Humalog® bolus) to be given very close to mealtime. The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. The faster onset of action compared to soluble human insulin is maintained regardless of injection site. As with all insulin preparations, the duration of action of Humalog® is dependent on dose, site of injection, blood supply, temperature, and physical activity.

Humalog® can be used in conjunction with a longer-acting human insulin or oral sulphonylurea agents, on the advice of a physician.

Contraindications

Humalog® is contraindicated during episodes of hypoglycemia. Humalog® is contraindicated in patients with hypersensitivity to insulin lispro or any of the excipients contained in the formulation.

Special warnings and precautions for use

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, etc.), species (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA versus animal-source insulin) may result in the need for a change in dosage. For fast-acting insulins, any patient also on basal insulin must optimise dosage of both insulins to obtain glucose control across the whole day, particularly nocturnal/fasting glucose control. Conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, intensified insulin therapy, diabetic nerve disease or medications such as beta-blockers.

A few patients who have experienced hypoglycaemic reactions after transfer from animal-source insulin to human insulin have reported that the early warning symptoms of hypoglycaemia were less pronounced or different from those experienced with their previous insulin. Uncorrected hypoglycaemic or hyperglycaemic reactions can cause loss of consciousness, coma, or death.

The use of dosages which are inadequate or discontinuation of treatment, especially in insulin-dependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.

Insulin requirements may be reduced in the presence of renal impairment.

Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements.

Insulin requirements may be increased during illness or emotional disturbances.

Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia. A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia occurs, it may occur earlier after an injection when compared with soluble human insulin.

Combination of Humalog® with pioglitazone: Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind, if treatment with the combination of pioglitazone and Humalog® is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued, if any deterioration in cardiac symptoms occurs.

Humalog® should only be used in children in preference to soluble insulin when a fast action of insulin might be beneficial. For example, in the timing of the injections in relation to meals.

Instructions for use and handling

To prevent the possible transmission of disease, each cartridge must be used by one patient only, even if the needle on the delivery device is changed.

Interaction with other medicinal products and other forms of interaction

Insulin requirements may be increased by medicinal products with hyperglycaemic activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta₂ stimulants (such as ritodrine, salbutamol, terbutaline).

Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity, such as oral hypoglycemics, salicylates (for example, acetylsalicylic acid), sulpha antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide or alcohol.

The physician should be consulted when using other medications in addition to Humalog®. (see also section *Special warnings and precautions for use*).

Fertility, pregnancy and lactation

Data on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro on pregnancy or on the health of the foetus/newborn. It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient throughout pregnancy. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Patients with diabetes should be advised to inform their doctor if they are pregnant or are contemplating pregnancy. Careful monitoring of glucose control, as well as general health, is essential in pregnant patients with diabetes. Patients with diabetes who are breast-feeding may require adjustments in insulin dose, diet or both.

Effects on ability to drive and use machines

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).

Patients should be advised to take precautions to avoid hypoglycaemia whilst driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.

Undesirable effects

Hypoglycaemia is the most frequent undesirable effect of insulin therapy that a patient with diabetes may suffer. Severe hypoglycaemia may lead to loss of consciousness, and in extreme cases, death. No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors e.g. a patient's level of diet and exercise.

Local allergy in patients is common (1/100 to <1/10). Redness, swelling, and itching can occur at the site of insulin injection. This condition usually resolves in a few days to a few weeks. In some instances, this condition may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique. Systemic allergy, which is rare (1/10,000 to <1/1,000) but potentially more serious, is a generalised allergy to insulin. It may cause a rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalised allergy may be life-threatening.

Lipodystrophy at the injection site is uncommon (1/1,000 to <1/100).

SPONTANEOUS DATA:

Cases of edema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy (see section *Special warnings and precautions for use*).

Overdose

Insulins have no specific overdose definitions because serum glucose concentrations are a result of complex interactions between insulin levels, glucose availability and other metabolic processes. Hypoglycaemia may occur as a result of an excess of insulin activity relative to food intake and energy expenditure.

Hypoglycaemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.

Mild hypoglycaemic episodes will respond to oral administration of glucose or other sugar or saccharated products.

Correction of moderately severe hypoglycaemia can be accomplished by intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate when the patient recovers sufficiently. Patients who fail to respond to glucagon must be given glucose solution intravenously.

If the patient is comatose, glucagon should be administered intramuscularly or subcutaneously. However, glucose solution must be given intravenously if glucagon is not available or if the patient fails to respond to glucagon. The patient should be given a meal as soon as consciousness is recovered.

Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.

Item Code PA007ITRI05		Previous Item Code (to be destroyed) PA007ITRI04			
PPD Information Box				ALRP Information Box	
Start Date 12 MAR 2018	Proof No. : 2	Printing Colours BLACK	Technical Colours Die Cut	Affiliate Barcode: Type: N/A Code: N/A	Translations of Variable Data
Technical Information: Layout name SES5PA200A00	Size (mm): 320x210			Other Regulated Elements N/A	lot: N/A
	Folded Size (mm) 80x54				mfg date: N/A
	No. of Pages: 1/2				exp date: N/A
BLUE Project No. 1800029798	Sick Code N/A	Overt N/A		price: N/A	other: N/A
Feed Direction: (For labels only)	N/A <input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Answers That Matter. v5.4				Site: Sesto	
		Riverside Drive, Cleckheaton, West Yorkshire, BD19 4DH, United Kingdom Tel: +44 (0) 127 484 8000 www.schawki.com		Internal to Schawki (no Lilly check required) Schawki Artwork Ref: 100786577_400868623 Operator Name: BS	

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Pharmacotherapeutic group :Fast-acting human insulin analogue. ATC code: A10A B04


The primary activity of insulin lispro is the regulation of glucose metabolism.

In addition, insulins have several anabolic and anti-catabolic actions on a variety of different tissues. Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.

Insulin lispro has a rapid onset of action (approximately 15 minutes), thus allowing it to be given closer to a meal (within zero to 15 minutes of the meal) when compared to regular insulin (30 to 45 minutes before). Insulin lispro takes effect rapidly and has a shorter duration of activity (2 to 5 hours) when compared to regular insulin.

Clinical trials in patients with type 1 and type 2 diabetes have demonstrated reduced postprandial hyperglycaemia with insulin lispro compared to soluble human insulin.

As with all insulin preparations, the time course of insulin lispro action may vary in different individuals or at different times in the same individual and is dependent on dose, site of injection, blood supply, temperature and physical activity. The typical activity profile following subcutaneous injection is illustrated below.



The above representation reflects the relative amount of glucose over time required to maintain the subject's whole blood glucose concentrations near fasting levels and is an indicator of the effect of these insulins on glucose metabolism over time.

Clinical trials have been performed in children (61 patients aged 2 to 11) and children and adolescents (481 patients aged 9 to 19 years), comparing insulin lispro to human soluble insulin. The pharmacodynamic profile of insulin lispro in children is similar to that seen in adults.

When used in subcutaneous infusion pumps, treatment with insulin lispro has been shown to result in lower glycosylated haemoglobin levels compared to soluble insulin. In a double-blind, crossover study, the reduction in glycosylated haemoglobin levels after 12 weeks dosing was 0.37 percentage points with insulin lispro, compared to 0.03 percentage points for soluble insulin ($p = 0.004$).

In patients with type 2 diabetes on maximum doses of sulphonyl urea agents, studies have shown that the addition of insulin lispro significantly reduces HbA_{1c} compared to sulphonyl urea alone. The reduction of HbA_{1c} would also be expected with other insulin products e.g. soluble or isophane insulins.

Clinical trials in patients with type 1 and type 2 diabetes have demonstrated a reduced number of episodes of nocturnal hypoglycaemia with insulin lispro compared to soluble human insulin. In some studies, reduction of nocturnal hypoglycaemia was associated with increased episodes of daytime hypoglycaemia.

The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment. Glucodynamic differences between insulin lispro and soluble human insulin, as measured during a glucose clamp procedure, were maintained over a wide range of renal function.

Insulin lispro has been shown to be equipotent to human insulin on a molar basis but its effect is more rapid and of a shorter duration.

Pharmacokinetic properties

The pharmacokinetics of insulin lispro reflect a compound that is rapidly absorbed, and achieves peak blood levels 30 to 70 minutes following subcutaneous injection. When considering the clinical relevance of these kinetics, it is more appropriate to examine the glucose utilisation curves (as discussed in section *Pharmacodynamic properties*).

Insulin lispro maintains more rapid absorption when compared to soluble human insulin in patients with renal impairment. In patients with type 2 diabetes over a wide range of renal function the pharmacokinetic differences between insulin lispro and soluble human insulin were generally maintained and shown to be independent of renal function. Insulin lispro maintains more rapid absorption and elimination when compared to soluble human insulin in patients with hepatic impairment.

Preclinical safety data

In *in vitro* tests, including binding to insulin receptor sites and effects on growing cells, insulin lispro behaved in a manner that closely resembled human insulin. Studies also demonstrate that the dissociation of binding to the insulin receptor of insulin lispro is equivalent to human insulin. Acute, one month and twelve month toxicology studies produced no significant toxicity findings.

Insulin lispro did not induce fertility impairment, embryotoxicity or teratogenicity in animal studies.

PHARMACEUTICAL PARTICULARS

List of excipients

Glycerol
Metaresol
Zinc Oxide
Dibasic Sodium Phosphate
Hydrochloric Acid
Sodium Hydroxide
Water for Injection

Incompatibilities

Humalog® preparations should not be mixed with insulins produced by other manufacturers or with animal insulin preparations.

Shelf life

3 years

After insertion of the cartridge in a pen, the solution should be used in 28 days when stored below 30°C.

Special precautions for storage

Store at 2°C - 8°C (in a refrigerator). Do not freeze. Do not expose to excessive heat or direct sunlight. Once in use cartridges may be used for up to 28 days. Following insertion in a pen, the cartridge and pen should be stored below 30°C and should not be refrigerated.

The pen with the inserted cartridge should not be stored with the needle attached.

Nature and contents of container

The solution is contained in type I flint glass cartridges, sealed with butyl or halobutyl disc seals and plunger heads, and are secured with aluminium seals. Dimeticone or silicone emulsion may be used to treat the cartridge plungers, and/or the glass cartridges.

Humalog® is available in a pack of 5 x 3 mL Humalog® cartridges for a 3 mL pen

Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

Instructions for use and handling

To prevent the possible transmission of disease, each cartridge must be used by one patient only, even if the needle on the delivery device is changed.

Instructions for use, handling and disposal

NEVER SHARE INSULIN PENS, EXTERNAL INSULIN PUMPS, INFUSION SETS, CARTRIDGES, OR NEEDLES.

a) Preparing a dose

Inspect the Humalog® solution. It should be clear and colourless. Do not use Humalog® if it appears cloudy, thickened, or slightly coloured or if solid particles are visible.

The following is a general description. The manufacturer's instructions with each individual pen must be followed for loading the cartridge, attaching the needle and administering the insulin injection.

b) Injecting a dose

1. Wash your hands.
2. Choose a site for injection.
3. Clean the skin as instructed.
4. Remove outer needle cap.
5. Stabilise the skin by spreading it or pinching up a large area. Insert the needle as instructed.
6. Press the knob.
7. Pull the needle out and apply gentle pressure over the injection site for several seconds. Do not rub the area.
8. Using the outer needle cap, unscrew the needle and dispose of it safely.
9. Use of injection sites should be rotated so that the same site is not used more than approximately once a month.

c) Mixing insulins

Do not mix insulin in vials with insulin in cartridges. See section *Incompatibilities*.

d) Use of Humalog® in an insulin infusion pump:

Only certain CE-marked insulin infusion pumps may be used to infuse insulin lispro. Before infusing insulin lispro, the manufacturer's instructions should be studied to ascertain the suitability or otherwise for the particular pump. Read and follow the instructions that accompany the infusion pump. Use the correct reservoir and catheter for the pump. The infusion set (tubing and cannula) should be changed in accordance with the instructions in the product information supplied with the infusion set. Use aseptic technique when inserting the infusion set. In the event of a hypoglycaemic episode, the infusion should be stopped until the episode is resolved. If repeated or severe low blood glucose levels occur, notify your health care professional and consider the need to reduce or stop your insulin infusion. A pump malfunction or obstruction of the infusion set can result in a rapid rise in glucose levels. If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your health care professional. When used with an insulin infusion pump, Humalog® should not be mixed with any other insulin.

e) Intravenous administration of insulin:

Intravenous injection of insulin lispro should be carried out following normal clinical practice for intravenous injections, for example by an intravenous bolus or by an infusion system. Frequent monitoring of the blood glucose levels is required. Infusion systems at concentrations from 0.1U/mL to 1.0U/mL insulin lispro in 0.9% sodium chloride or 5% dextrose are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion to the patient.

Manufactured by :

M/s. Eli Lilly Italia S.P.A.,
via Gramsci 731-733,
50019 Sesto Fiorentino (FI),
Italy

*Marketed By:

Eli Lilly and Company (India) Pvt. Ltd.
Plot No. 92, Sector-32, Gurgaon-122001, Haryana, India

Imported By:

Eli Lilly and Company (India) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4,
1st Fl, Arihant Comm. Complex, Purna Bhiwandi, Maharashtra-421302

If you have any questions or complaints with your Humalog cartridge, contact Lilly at Toll Free number 18001230021 or your healthcare professional for assistance

*Under licence from registered trademark owners

Eli Lilly and Company, USA

Humalog® cartridges are designed to be used only with Lilly Insulin delivery devices

For more information, visit us at www.lillyindia.co.in

PA007ITRI05

Item Code PA007ITRI05		Previous Item Code (to be destroyed) PA007ITRI04	
PPD Information Box			ALRP Information Box
Start Date 12 MAR 2018	Proof No. : 2	Printing Colours BLACK	Technical Colours Die Cut
Technical Information: Layout name SES/PA200A00	Size (mm): 320x210		Affiliate Barcode: Type: N/A Code: N/A
	Folded Size (mm) 80x54		
	No. of Pages: 2/2		
Other Regulated Elements N/A	lot: N/A		
BLUE Project No. 1800029798	Sick Code N/A	Overt N/A	mfg date: N/A
Feed Direction: (For labels only)	N/A	<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	exp date: N/A
			price: N/A
			other: N/A
SCHAWKI! Riverside Drive, Cleckheaton, West Yorkshire, BD19 4DH, United Kingdom Tel. +44 (0) 127 484 8000 www.schawki.com			Site: Sesto
Internal to Schawk (no Lilly check required)			
Schawk Artwork Ref: 100786577_400868623			
Operator Name: BS			